摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-[(3-吡啶)甲基]哌嗪 | 39244-80-9

中文名称
1-[(3-吡啶)甲基]哌嗪
中文别名
1-(3-吡啶甲基)哌嗪;1-吡啶-3-基甲基哌嗪;1-(3-吡啶基甲基)哌嗪
英文名称
1-(pyridin-3-ylmethyl)piperazine
英文别名
1-(3-pyridylmethyl)piperazine;(pyridin-3-ylmethyl)piperazine;4-(pyridin-3-yl-methyl)-piperazine;1-[(3-pyridyl)-methyl]-piperazine;1-pyridin-3-ylmethyl-piperazine;(3-pyridylmethyl)piperazine
1-[(3-吡啶)甲基]哌嗪化学式
CAS
39244-80-9
化学式
C10H15N3
mdl
MFCD01862552
分子量
177.249
InChiKey
UNGUQQBXDOAOQO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    84 °C
  • 密度:
    1.073

计算性质

  • 辛醇/水分配系数(LogP):
    -0.2
  • 重原子数:
    13
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    28.2
  • 氢给体数:
    1
  • 氢受体数:
    3

安全信息

  • 危险等级:
    IRRITANT
  • 危险品标志:
    Xi
  • 危险类别码:
    R36/37/38
  • 海关编码:
    2933990090
  • 安全说明:
    S26,S36/37/39
  • 危险性防范说明:
    P280
  • 危险性描述:
    H302+H312+H332
  • 储存条件:
    | 2-8°C |

SDS

SDS:130ec3ecbf7b630f3444943f292f1963
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 1-Pyridin-3-ylmethyl-piperazine
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 1-Pyridin-3-ylmethyl-piperazine
CAS number: 39244-80-9

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C10H15N3
Molecular weight: 177.2

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    1-[(3-吡啶)甲基]哌嗪sodium acetate 作用下, 以 乙腈 为溶剂, 以75%的产率得到2-(4-(pyridin-3-ylmethyl)piperazin-1-yl)pyrazine
    参考文献:
    名称:
    碘介导的 N-烷基哌嗪一锅法合成 2-(哌嗪-1-基)吡嗪衍生物
    摘要:
    首次描述了碘介导的 N-烷基哌嗪的一锅反应。这种转化为合成 2-(哌嗪-1-基) 吡嗪衍生物提供了一条简单易行的途径,其中相应的 N-烷基哌嗪作为单一材料。基于一系列控制实验,提出了一个合理的反应机制。
    DOI:
    10.1055/s-0036-1588701
  • 作为产物:
    描述:
    3-吡啶甲醇 在 polymer supported cyanoborohydride 、 polymer supported perruthenate 作用下, 以 甲醇甲苯 为溶剂, 反应 74.0h, 生成 1-[(3-吡啶)甲基]哌嗪
    参考文献:
    名称:
    Ley, Steven V.; Bolli, Martin H.; Hinzen, Berthold, Journal of the Chemical Society. Perkin transactions I, 1998, # 15, p. 2239 - 2241
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • Synthesis and biological evaluation as AChE inhibitors of new indanones and thiaindanones related to donepezil
    作者:Ziad Omran、Thomas Cailly、Elodie Lescot、Jana Sopkova-de Oliveira Santos、Jean-Hugues Agondanou、Vincent Lisowski、Frédéric Fabis、Anne-Marie Godard、Silvia Stiebing、Guillaume Le Flem、Michel Boulouard、François Dauphin、Patrick Dallemagne、Sylvain Rault
    DOI:10.1016/j.ejmech.2005.07.009
    日期:2005.12
    Sixty-four new indanones and thiaindanones related to donepezil were synthesized and evaluated in vitro as potential AChE inhibitors. Among them, 11 derivatives were found to inhibit the enzyme in the submicromolar range; the best compound revealed its inhibitory activity with an IC50 in the same range (0.06 microM) than the reference compound, donepezil (IC50=0.02 microM).
    合成了与多奈哌齐有关的六十四种新的茚满酮和硫丹酮,并在体外评估了其作为潜在的AChE抑制剂。其中,发现了11种衍生物在亚微摩尔范围内抑制该酶。最好的化合物显示出其抑制活性,其IC50与参考化合物多奈哌齐(IC50 = 0.02 microM)处于相同范围(0.06 microM)。
  • Compounds and uses thereof for decreasing activity of hormone-sensitive lipase
    申请人:——
    公开号:US20030166644A1
    公开(公告)日:2003-09-04
    Use of compounds to inhibit hormone-sensitive lipase, pharmaceutical compositions comprising the compounds, methods of treatment employing these compounds and compositions, and novel compounds. The present compounds are inhibitors of hormone-sensitive lipase and may be useful in the treatment and/or prevention of medical disorders where a decreased activity of hormone-sensitive lipase is desirable.
    使用化合物抑制激素敏感性脂肪酶,包括这些化合物的药物组合物,使用这些化合物和组合物的治疗方法,以及新化合物。目前的化合物是激素敏感性脂肪酶抑制剂,可能在治疗和/或预防需要降低激素敏感性脂肪酶活性的医学疾病中有用。
  • [EN] 6H-THIENO`2, 3-B!PYRROLE DERIVATIVES AS ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE (GNRH)<br/>[FR] DERIVES DE 6H-THIENO`2,3-B!PYRROLE EN TANT QU'ANTAGONISTES DE LA GONADOLIBERINE (GNRH)
    申请人:ASTRAZENECA AB
    公开号:WO2004018480A1
    公开(公告)日:2004-03-04
    The invention relates to a group of novel thieno-pyrrole compounds of Formula (I): wherein: R1, R2, R3, R4 and R5 are as defined in the specification, which are useful as gonadotrophin releasing hormone antagonists. The invention also relates to pharmaceutical formulations of said compounds, methods of treatment using said compounds and to processes for the preparation of said compounds.
    这项发明涉及一组新型噻吩-吡咯烷化合物的化学式(I):其中:R1、R2、R3、R4和R5如规范中定义,这些化合物可用作促性腺激素释放激素拮抗剂。该发明还涉及所述化合物的药物配方、使用所述化合物的治疗方法以及所述化合物的制备方法。
  • Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents
    作者:Rui Xie、Yan Li、Pingwah Tang、Qipeng Yuan
    DOI:10.1016/j.ejmech.2017.08.041
    日期:2018.1
    HDAC2 selective inhibitors. We also rationalize the high potency and selectivity of compound M122 by molecular docking. Further investigation showed that M101, M122 and M133 could inhibit colony formation of human hepatocellular carcinoma cell line SMMC7721. Furthermore, M101, M122 and M133 remarkably induced apoptosis in SMMC7721 cancer cells. M101 and M133 were found to potently induce SMMC7721 cancer
    设计并合成了一系列以二氨基甲酸酯为帽基的新型2-基苯甲酰胺,作为组蛋白脱乙酰基酶(HDAC抑制剂。大多数新合成的化合物对多种人类肿瘤细胞系均显示出强大的抗增殖活性。最有效的化合物M101,M122和M133在IC 50的作用下,对6种癌细胞系表现出显着增强的抗癌能力与CS055(2.28〜> 26μM)和MS275(0.47–6.74μM)相比,该值低至0.54–2.49μM。HDAC同工型选择性测定表明M101,M122和M133是HDAC1和HDAC2选择性抑制剂。我们还通过分子对接合理化了化合物M122的高效价和选择性。进一步的研究表明,M101,M122和M133可以抑制人肝癌细胞SMMC7721的集落形成。此外,M101,M122和M133显着诱导SMMC7721癌细胞的凋亡。发现M101和M133在G2 / M期有效诱导SMMC7721癌细胞周期停滞。这项研究表明,引入
  • Pyrazolo [1,5-A] pyrimidine adenosine A2a receptor antagonists
    申请人:Clasby C. Martin
    公开号:US20060135526A1
    公开(公告)日:2006-06-22
    Compounds having the structural formula I are disclosed, wherein A is alkylene, or optionally substituted arylene, cycloalkylene or heteroaryldiyl; X is —C(O)— or —S(O) 2 —; R 1 is alkyl or cycloalkyl; R 2 is hydrogen, halo or —CN; R 3 is hydrogen or alkyl; R 4 is hydrogen, alkyl, alkoxy, hydroxyalkyl, aminoalkyl-, cycloalkyl, heterocycloalkyl, heterocycloalkyl substituted by alkyl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl; or R 3 and R 4 , form an optionally substituted 5-7 membered ring, said ring optionally comprising an additional heteroatom ring member; R 7 is alkyl, optionally substituted phenyl, optionally substituted heteroaryl, cycloalkyl, halo, morpholinyl, optionally substituted piperazinyl, or optionally substituted azacycloalkyl. Also disclosed is the use of the compounds in the treatment of Parkinson's disease, alone or in combination with other agents for treating Parkinson's disease, pharmaceutical compositions comprising them and kits comprising the components of the combinations.
    揭示了具有结构式I的化合物,其中A是烷基,或者可选择地取代的芳基,环烷基或杂芳基二基;X是—C(O)—或—S(O)2—;R1是烷基或环烷基;R2是氢,卤素或—CN;R3是氢或烷基;R4是氢,烷基,烷氧基,羟基烷基,基烷基,环烷基,杂环烷基,被烷基取代的杂环烷基,可选择地取代的芳基烷基或可选择地取代的杂芳基烷基;或者R3和R4形成一个可选择地取代的5-7成员环,所述环可选择地包含一个额外的杂原子环成员;R7是烷基,可选择地取代的苯基,可选择地取代的杂芳基,环烷基,卤素,吗啉基,可选择地取代的哌嗪基,或可选择地取代的氮杂环烷基。还揭示了这些化合物在帕森病治疗中的用途,单独或与其他治疗帕森病的药剂组合使用,包含它们的药物组合物和包含组合物组分的工具包。
查看更多

同类化合物

(乙腈)二氯镍(II) (R)-(-)-α-甲基组胺二氢溴化物 (N-(2-甲基丙-2-烯-1-基)乙烷-1,2-二胺) (4-(苄氧基)-2-(哌啶-1-基)吡啶咪丁-5-基)硼酸 (11-巯基十一烷基)-,,-三甲基溴化铵 鼠立死 鹿花菌素 鲸蜡醇硫酸酯DEA盐 鲸蜡硬脂基二甲基氯化铵 鲸蜡基胺氢氟酸盐 鲸蜡基二甲胺盐酸盐 高苯丙氨醇 高箱鲀毒素 高氯酸5-(二甲氨基)-1-({(E)-[4-(二甲氨基)苯基]甲亚基}氨基)-2-甲基吡啶正离子 高氯酸2-氯-1-({(E)-[4-(二甲氨基)苯基]甲亚基}氨基)-6-甲基吡啶正离子 高氯酸2-(丙烯酰基氧基)-N,N,N-三甲基乙铵 马诺地尔 马来酸氢十八烷酯 马来酸噻吗洛尔EP杂质C 马来酸噻吗洛尔 马来酸倍他司汀 顺式环己烷-1,3-二胺盐酸盐 顺式氯化锆二乙腈 顺式吡咯烷-3,4-二醇盐酸盐 顺式双(3-甲氧基丙腈)二氯铂(II) 顺式3,4-二氟吡咯烷盐酸盐 顺式1-甲基环丙烷1,2-二腈 顺式-二氯-反式-二乙酸-氨-环己胺合铂 顺式-二抗坏血酸(外消旋-1,2-二氨基环己烷)铂(II)水合物 顺式-N,2-二甲基环己胺 顺式-4-甲氧基-环己胺盐酸盐 顺式-4-环己烯-1.2-二胺 顺式-4-氨基-2,2,2-三氟乙酸环己酯 顺式-3-氨基环丁烷甲腈盐酸盐 顺式-2-羟基甲基-1-甲基-1-环己胺 顺式-2-甲基环己胺 顺式-2-(苯基氨基)环己醇 顺式-2-(苯基氨基)环己醇 顺式-2-(氨基甲基)-1-苯基环丙烷羧酸盐酸盐 顺式-1,3-二氨基环戊烷 顺式-1,2-环戊烷二胺二盐酸盐 顺式-1,2-环戊烷二胺 顺式-1,2-环丁腈 顺式-1,2-双氨甲基环己烷 顺式--N,N'-二甲基-1,2-环己二胺 顺式-(R,S)-1,2-二氨基环己烷铂硫酸盐 顺式-(2-氨基-环戊基)-甲醇 顺-2-戊烯腈 顺-1,3-环己烷二胺 顺-1,3-双(氨甲基)环己烷